Back to discover
Disease

Lymphoma

Late-stage therapeutic developmentEmerging researchSteady momentum
MeSHLymphoma
17
Publications
24
Clinical trials
3
Related conditions
12
Associated genes
12
Related proteins
2025
Latest publication
Current focus
Perforin-1 biologyTherapeutic developmentXanthine dehydrogenase/oxidase biologyInflammation & immunity
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

A Phase Ib Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical trial2026-10-06Status changed to Active, not recruiting · ClinicalTrials.gov

PH-139: A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Clinical trial2026-09-21Status changed to Suspended · ClinicalTrials.gov

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-07: A Phase 1/2 Study of CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma

Clinical trial2026-09-11Results posted · ClinicalTrials.gov

ABBA CORD: Double Umbilical Cord Blood Transplants With Abatacept for Graft Versus Host Disease Prophylaxis

Clinical trial2026-09-10Status changed to Suspended · ClinicalTrials.gov

A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Clinical trial2026-08-18Results posted · ClinicalTrials.gov

A Phase I Study of Autologous Activated T-cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Subjects With Relapsed/Refractory B-cell Lymphoma

Clinical trial2026-07-31Results posted · ClinicalTrials.gov

Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Period in Patients With Multiple Myeloma, Relapsed Hodgkin's and Non-Hodgkin's Lymphoma

Clinical trial2026-07-23Status changed to Active, not recruiting · ClinicalTrials.gov

Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression

Clinical trial2026-07-17Status changed to Completed · ClinicalTrials.gov

Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025).

Research2025-11-27Journal of hematology & oncology

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.

Research2024-07-08Nature medicine

Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.

Research2024-04-01Journal of nuclear medicine : official publication, Society of Nuclear Medicine

IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts.

Research2024-02-09Journal of hematology & oncology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q2 2027.
  • Active recent publication activity.
  • 12 industry developments reported.
Upcoming Milestones
Research Highlights1View
Clinical Milestones6View
Results expected 5
Industry & Market12View all 12
+7 more in the activity timeline below
Regulatory Updates1View
  • 2026-02-16Product authorisation ended — DuvelisibCopiktra monotherapy is indicated for the treatment of adult patients with:  Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies.  Follicular lymphoma (FL) that is refractory to at least two prior  systemic therapies.
Activity timeline20

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Duvelisibapproved

Product authorisation ended — Copiktra monotherapy is indicated for the treatment of adult patients with:  Relapsed or… (2026)

Bortezomibapproved

Product authorisation ended — Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin… (2025)

Ibritumomab tiuxetanapproved

Product authorisation ended — Zevalin is indicated in adults. [90Y]-radiolabelled Zevalin is indicated as consolidation… (2024)

Odronextamabapproved

Conditional marketing authorisation — Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or… (2024)

Epcoritamabapproved

Conditional marketing authorisation — Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or… (2023)

Glofitamabapproved

Original application approval — Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of… (2023)

Pirtobrutinibapproved

Conditional marketing authorisation — Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or… (2023)

Lisocabtagene maraleucelapproved

Original application approval — Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymph… (2022)

Loncastuximab tesirineapproved

Conditional marketing authorisation — Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or… (2022)

Mosunetuzumabapproved

Conditional marketing authorisation — Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or… (2022)

Plerixaforapproved

Generic approval — Adult patients Plerixafor Accord is indicated in combination with granulocyte-colony stim… (2022)

Lenalidomideapproved

Generic approval — Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatme… (2021)

Tafasitamabapproved

Conditional marketing authorisation — Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for… (2021)

Zanubrutinibapproved

Original application approval — Brukinsa as monotherapy is indicated for the treatment of adult patients with Walden… (2021)

Acalabrutinibapproved

Original application approval — Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatme… (2020)

Dimethyl fumarateapproved

Generic approval — Multiple myeloma Lenalidomide Mylan as monotherapy is indicated for the maintenance treat… (2020)

Melphalan hydrochlorideapproved

Original application approval — High-dose of Phelinun used alone or in combination with other cytotoxic medicinal product… (2020)

Clinical trials

15 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Phase 3 · Active, not recruiting · Genmab

A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations

Phase 3 · Active, not recruiting · Merck Sharp & Dohme LLC

A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Phase 3 · Active, not recruiting · Hoffmann-La Roche

A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL)

Phase 3 · Active, not recruiting · Novartis Pharmaceuticals

Phase 3, Interventional, Multicentre, Open-label, Randomized Study Comparing Rituximab Plus Zanubrutinib to Rituximab Monotherapy in Previously Untreated, Symptomatic Splenic Marginal Zone Lymphoma (RITZ)

Phase 3 · Active, not recruiting · International Extranodal Lymphoma Study Group (IELSG)

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors

Phase 3 · Active, not recruiting · BeOne Medicines
Recently completed

A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease

Phase 3 · Completed · Children's Oncology Group

BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma

Phase 3 · Completed · European Organisation for Research and Treatment of Cancer - EORTC

Randomized Phase III Trial Of Rituximab (NSC #687451) And Autologous Stem Cell Transplantation For B Cell Diffuse Large Cell Lymphoma

Phase 3 · Completed · Eastern Cooperative Oncology Group

Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody Versus Observation Following Induction Therapy

Phase 3 · Completed · National Cancer Institute (NCI)

A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)

Phase 3 · Completed · Fondazione Italiana Linfomi - ETS

Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma

Phase 3 · Completed · Biogen

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2024emaConditional marketing authorisation — Odronextamab· Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy. source ↗
2023emaConditional marketing authorisation — Pirtobrutinib· Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a BTK inhibitor. source ↗
2023emaConditional marketing authorisation — Epcoritamab· Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.  source ↗
2022emaConditional marketing authorisation — Loncastuximab tesirine· Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. source ↗
2022emaConditional marketing authorisation — Mosunetuzumab· Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. source ↗
2021emaConditional marketing authorisation — Tafasitamab· Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). source ↗
Product approvals and authorisations
2023emaOriginal application approval — Glofitamab· Columvi in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT).Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy. source ↗
2022emaGeneric approval — Plerixafor· Adult patients Plerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2). Paediatric patients (1 to less than 18 years) Plerixafor Accord is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.2). source ↗
2022emaOriginal application approval — Lisocabtagene maraleucel· Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.   Breyanzi is indicated for the treatment of adult patients with relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy.  Breyanzi is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.   Breyanzi is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.  source ↗
2021emaOriginal application approval — Zanubrutinib· Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy. Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). Brukinsa in combination with obinutuzumab is indicated for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. source ↗
2021emaGeneric approval — Lenalidomide· Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1). Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). Multiple myelomaLenalidomide Krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Myelodysplastic syndromesLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. Mantle cell lymphomaLenalidomide Krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4.4 and 5.1). Follicular lymphomaLenalidomide Krka in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). source ↗
2020emaGeneric approval — Dimethyl fumarate· Multiple myeloma Lenalidomide Mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. Lenalidomide Mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. Lenalidomide Mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Follicular lymphoma Lenalidomide Mylan in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a). source ↗
2020emaOriginal application approval — Melphalan hydrochloride· High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of: multiple myeloma, malignant lymphoma (Hodgkin, non-Hodgkin lymphoma), acute lymphoblastic and myeloblastic leukemia, childhood neuroblastoma, ovarian cancer, mammary adenocarcinoma. Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults. Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as: Myeloablative conditioning (MAC) treatment in case of malignant haematological diseases RIC treatment in case of non-malignant haematological diseases. source ↗
2020emaOriginal application approval — Acalabrutinib· Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence in combination with venetoclax with or without obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.Calquence in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT).Calquence as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) not previously treated with a BTK inhibitor. source ↗
Other regulatory activity
2026emaProduct authorisation ended — Duvelisib· Copiktra monotherapy is indicated for the treatment of adult patients with:  Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies.  Follicular lymphoma (FL) that is refractory to at least two prior  systemic therapies. source ↗
2025emaProduct authorisation ended — Bortezomib· Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation. Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation. source ↗
2024emaProduct authorisation ended — Ibritumomab tiuxetan· Zevalin is indicated in adults. [90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. [90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

17 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
1994–2025
Most influential

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Blood · 1994 · 3,350 cites

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Leukemia · 2022 · 2,709 cites

Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Journal of immunology (Baltimore, Md. : 1950) · 2005 · 1,380 cites

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.

Blood · 2022 · 1,127 cites

Engineering strategies to overcome the current roadblocks in CAR T cell therapy.

Nature reviews. Clinical oncology · 2020 · 1,111 cites

B lymphocytes: how they develop and function.

Blood · 2008 · 863 cites
Recent publications

Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025).

Journal of hematology & oncology · 2025 · 3 cites

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.

Nature medicine · 2024 · 190 cites

IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts.

Journal of hematology & oncology · 2024 · 73 cites

Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024 · 37 cites

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Leukemia · 2022 · 2,709 cites

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.

Blood · 2022 · 1,127 cites
Major themes8
  • Lymphoma7
  • Hematologic Neoplasms2
  • Neoplasms2
  • Breast Neoplasms1
  • Cancer-Associated Fibroblasts1
  • Cell- and Tissue-Based Therapy1
  • Head and Neck Neoplasms1
  • Hematopoietic Stem Cell Mobilization1
Leading journals6
  • Blood4
  • Journal of hematology & oncology4
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
  • Hematological oncology1
  • Journal of immunology (Baltimore, Md. : 1950)1
  • Journal of medicinal chemistry1
Leading researchers8
  • Advani R2
  • Ansell S2
  • Chen X2
  • Falini B2
  • Ghobrial IM2
  • Jaffe ES2
  • Kumar S2
  • Ajami B1
Affiliations (unnormalised)6
  • Dana-Farber Cancer Institute4
  • Mayo Clinic3
  • Memorial Sloan Kettering Cancer Center3
  • The University of Texas MD Anderson Cancer Center3
  • Center for Cancer Research2
  • Columbia University Irving Medical Center2

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

XDH0.60CXCR40.52FAS0.51PRF10.48WAS0.47LIG40.47SH2D1A0.47ALK0.47BLM0.46DOCK80.46CASP100.46EZH20.44

Disease biology

12 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Xanthine dehydrogenase/oxidasevia XDH0.60C-X-C chemokine receptor type 4via CXCR40.52Perforin-1via PRF10.48Actin nucleation-promoting factor WASvia WAS0.47ALK tyrosine kinase receptorvia ALK0.47Histone-lysine N-methyltransferase EZH2via EZH20.44Echinoderm microtubule-associated protein-like 4via EML40.41B-cell lymphoma 6 proteinvia BCL60.40Signal transducer and activator of transcription 6via STAT60.39Interleukin-3 receptor subunit alphavia IL3RA0.37B-cell receptor CD22via CD220.30Tumor necrosis factor ligand superfamily member 13Bvia TNFSF13B0.27

Related conditions

3 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Neoplasms4Hematologic Neoplasms2Multiple Myeloma2

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Lymphoma is a general term for a group of neoplastic diseases arising from lymphoid tissue. The supplied grounding indicates that it includes multiple distinct lymphoid neoplasms classified within the WHO haematolymphoid tumour system.

Pathophysiology

Lymphoma reflects malignant transformation of lymphoid cells, with the grounding emphasizing both pathology and immunology. The literature also highlights immune-related biology in lymphoma, including B- and T-lymphocyte lineage features, immunologic cytotoxicity, and responses to immune-based therapies such as CAR T cells and checkpoint blockade.

Current standard of care

Treatment is described at the modality and drug-class level as chemotherapy, chemoimmunotherapy, immunomodulatory therapy, immune checkpoint inhibitors, and CAR T-cell therapy for selected B-cell lymphomas. The grounding also includes HDAC inhibitors as a cancer-therapy class studied in lymphoma, and immunoconjugates as another relevant therapeutic modality.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A general term for various neoplastic diseases of the lymphoid tissue.

Identifiers
MeSHLymphoma
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.